Study of vepugratinib for cancers with FGFR3 gene changes
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a specific change (mutation) in the FGFR3 gene.
- You must have advanced cancer that has spread or cannot be removed by surgery, or in some cases, early-stage bladder cancer.
- For most parts of the study, you need to have tumors that can be measured on scans.
- You need to be in reasonably good health (able to do light activities) to take part.
- You cannot have untreated or uncontrolled brain tumors or certain eye problems.
- You must not be pregnant or breastfeeding during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
This trial provides expanded access to vepugratinib, an experimental drug that targets a specific gene change (FGFR3) found in some solid tumors, including bladder cancer. It’s for people who have run out of standard treatment options and cannot join another study of the same drug.
This trial tests a combination of two drugs: pemigatinib (targets FGFR gene changes) and an immunotherapy (checkpoint inhibitor) for people with advanced solid tumors that have FGFR mutations. It may be a good option if standard treatments have failed and you have already tried immunotherapy.
This trial tests a targeted drug called pemigatinib for advanced solid tumors that have a specific change in the FGFR gene. The goal is to see if the drug can slow tumor growth for people who have few other treatment options.
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
This trial tests a targeted therapy called erdafitinib, either alone or combined with an immunotherapy drug (cetrelimab), for people with muscle-invasive bladder cancer that has a specific FGFR gene change. It may be an option if you cannot take cisplatin chemotherapy and have not had prior treatment for this cancer.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.